- Home
- CATO vs IMUX Comparison
CATO vs IMUX Comparison
Compare CATO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATO
- IMUX
- Stock Information
- Founded
- CATO 1946
- IMUX 2016
- Country
- CATO United States
- IMUX United States
- Employees
- CATO N/A
- IMUX N/A
- Industry
- CATO Clothing/Shoe/Accessory Stores
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- CATO Consumer Discretionary
- IMUX Health Care
- Exchange
- CATO Nasdaq
- IMUX Nasdaq
- Market Cap
- CATO 59.2M
- IMUX 67.8M
- IPO Year
- CATO N/A
- IMUX N/A
- Fundamental
- Price
- CATO $2.87
- IMUX $0.71
- Analyst Decision
- CATO
- IMUX Strong Buy
- Analyst Count
- CATO 0
- IMUX 6
- Target Price
- CATO N/A
- IMUX $11.60
- AVG Volume (30 Days)
- CATO 43.0K
- IMUX 2.5M
- Earning Date
- CATO 08-21-2025
- IMUX 08-07-2025
- Dividend Yield
- CATO 6.11%
- IMUX N/A
- EPS Growth
- CATO N/A
- IMUX N/A
- EPS
- CATO N/A
- IMUX N/A
- Revenue
- CATO $642,949,000.00
- IMUX N/A
- Revenue This Year
- CATO N/A
- IMUX N/A
- Revenue Next Year
- CATO N/A
- IMUX N/A
- P/E Ratio
- CATO N/A
- IMUX N/A
- Revenue Growth
- CATO N/A
- IMUX N/A
- 52 Week Low
- CATO $2.19
- IMUX $0.56
- 52 Week High
- CATO $6.70
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- CATO 53.03
- IMUX 38.90
- Support Level
- CATO $2.73
- IMUX $0.68
- Resistance Level
- CATO $2.99
- IMUX $0.74
- Average True Range (ATR)
- CATO 0.18
- IMUX 0.06
- MACD
- CATO -0.02
- IMUX 0.00
- Stochastic Oscillator
- CATO 30.14
- IMUX 17.73
About CATO Cato Corporation (The)
The Cato Corp operates as a specialty retailer of fashion apparel and accessories in the southeastern United States. Its primary objective is to be the fashion specialty retailer for fashion and value in its markets. The company operates through the following business segments: Retail and Credit. The Retail segment which generates the majority of revenue offers fashion specialty stores. The Credit segment involves credit card services.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.